LEO Pharma and PellePharm have entered an agreement of collaboration to advance innovative therapies for rare skin diseases, a.o. Gorlin Syndrome. With the agreement, LEO Pharma acquires a minority stake and an option to acquire PellePharma for DKK 5bn is also agreed. The phase 3 trial regarding Gorlin Syndrome is essential to LEO’s acquisition. Stake size is not disclosed.